中文

← All funding rounds

Genesis Molecular AI (formerly Genesis Therapeutics)

Also known as Genesis Therapeutics

United StatesDrug discoverySan Mateo, California, United StatesFounded 2019Private

Website · genesis.ml ↗

Builds AI models of how small molecules bind proteins (GEMS platform, Pearl structure model) and uses them for its own and partners' drug programs.

Disclosed total$252M
Rounds on record2
Latest round$200MSeries B · 2023-08-21
Last stated valuationNone stated
Investors named16
Research on record2highest level 2 · Computed

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date202120222023202420252026$52M$200MEvidencelevel of each research entry12345
Closed roundResearch entry, at its level

Latest round, Series B, 2023-08-21: the record then held no research entry for the company. The first research entry is dated 2025-10-28; the highest level so far is 2 (Computed).

Rounds and research, on one timeline

  1. 2026-06-03
    Research

    Level 2 · Computed

    Genesis says its Pearl system, given only an unbound protein structure, posed 78% of 802 ligands within its best 25 tries in OpenBind's EV-A71 benchmark, above every co-folding model OpenBind tested

    On this target a loop next to the pocket moves about 3.9 Å when a drug binds, and docking into the unbound structure succeeds under 5% of the time. A model that predicts that movement from sequence can be used on targets with no drug-bound crystal structure, which is where co-folding is meant to pay off.

    Timeline entry →genesis.ml ↗

  2. 2025-10-28
    Research

    Level 2 · Computed

    Genesis says its Pearl model places drug molecules in proteins about 14% better than AlphaFold 3

    Genesis ran the comparison itself. The 3.6x gain is on its own private targets, and Pearl runs only inside Genesis.

    Timeline entry →arxiv.org ↗

  3. 2023-08-21Series B
    Round

    $200M

    For: take wholly owned programs into the clinic

    Toward the clinic

    Total raised since inception over $280M.

    Co-lead · Andreessen Horowitz ✓Co-lead · unnamed life-sciences investorFidelityBlackRockNVentures (NVIDIA) ✓T. Rowe PriceRock Springs CapitalMenlo Ventures ✓Radical Ventures ✓

    On the deal: Vijay Pande (Founding General Partner, Andreessen Horowitz)

    Announced by the company · biopharmadive.com ↗

  4. 2020-12-02Series A
    Round

    $52M

    For: grow the team, AI technology and pipeline

    HiringModels and platform

    Release says a16z led the earlier seed round; seed amount not given.

    Lead · Rock Springs CapitalT. Rowe PriceAndreessen Horowitz ✓Menlo Ventures ✓Radical Ventures ✓Felicis Ventures ✓Jazz Venture Partners ✓Harpoon VenturesUlu VenturesMark LeslieJeffrey RothschildPropagator VenturesOpen Field Capital

    On the deal: Greg Yap (Board observer, Menlo Ventures); Jeffrey Rothschild (Angel investor); Kris Jenner (Co-founder and Managing Partner, Rock Springs Capital, joins the board); Mark Leslie (Angel investor); Vijay Pande (Led the seed; board observer, Andreessen Horowitz)

    The investor's own page says · Radical Ventures: 2020

    Announced by the company · biospace.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

On the investors' own sites

Investors that name this company on their own site, in a portfolio or their own announcement. A ✓ in a round marks the same investor.

Its investors also backed

Other companies on this page whose rounds name the same investor.